Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have identified the phosphorylation sites in monkey
p53
as well as specific changes in the phosphorylation state of free and complexed forms of simian virus 40 (SV40) large T antigen (T) and monkey
p53
isolate from SV40 lytically infected CV1 cells. Phosphopeptide analyses of free T and
p53
(To and p53o) and complexed T and
p53
(T+ and p53+) fractions indicated several quantitative increases in the specific phosphorylation of complexed forms of both proteins. The N terminus of monkey p53+ is phosphorylated at Ser-9, Ser-15, Ser-20, either Ser-33 or Ser-37, and at least one of Ser-90 to Ser-99. The C-terminal sites are Ser-315 and Ser-392. On comparing p53+ with p53o, we found that labeling of the two N-terminal phosphotryptic peptides encompassing residues 1 to 20 and 33 to 101 was increased fivefold and that Ser-315 was sevenfold more labeled than was Ser-392. When T+ was compared with To, the N-terminal peptide containing phosphorylation sites Ser-106 through Thr-124 was twofold more labeled, the peptide containing Ser-657 through Ser-679 was sixfold more labeled and contained up to four phosphorylated
serine
residues, and Ser-639 and Thr-701 appeared unchanged. Overall, T+ molecules appeared to contain 3.5 mol more of labeled phosphate than did To, with the N-terminal peptide appearing fully phosphorylated. The phosphopeptide patterns obtained for lytic T+ and To fractions were nearly identical to those found for wild-type SV40 T (stably complexed with mouse
p53
) and mutant 5080 T (defective for
p53
binding) expressed in transformed C3H10T1/2 cells (L. Tack, C. Cartwright, J. Wright, A. Srinivasan, W. Eckhart, K. Peden, and J. Pipas, J. Virol. 63:3362-3367, 1989). These results indicate that increases in specific phosphorylation sites in both T+ and p53+ correlate with the association of T with
p53
. The enhanced phosphorylation state may be a consequence of complex formation between T and
p53
or reflect an increased affinity of
p53
for highly phosphorylated forms of T.
...
PMID:Altered phosphorylation of free and bound forms of monkey p53 and simian virus 40 large T antigen during lytic infection. 131 Jul 51
We have analyzed in detail the phosphorylation of
p53
from normal (3T3) and simian virus 40 (SV40)-transformed (SV3T3) BALB/c mouse cells and from normal (F111) and SV40-transformed [FR(wt648)] rat cells by two-dimensional tryptic peptide mapping and phosphoamino acid analyses. To accommodate the different half-lives of
p53
in normal (half-life, 15 min) and transformed (half-life, 20 h) cells and possible differences in the rates of turnover of phosphate at specific sites, cells were labeled for 2 h (short-term labeling) or 18 h (long-term labeling). Depending on the labeling conditions, either close similarities or marked differences were observed in the phosphorylation patterns of
p53
from normal and transformed cells. After the 2-h labeling, the phosphorylation patterns of
p53
from normal and transformed mouse cells were quite similar. In contrast,
p53
from normal and transformed rat cells exhibited dramatic quantitative and qualitative differences under these labeling conditions. The reverse was found after an 18-h label leading to steady-state phosphorylation of
p53
in transformed cells: while
p53
in transformed mouse cells revealed a marked quantitative increase in phosphorylation compared with
p53
from normal cells, the corresponding patterns of
p53
from normal and transformed rat cells were similar. Our data thus indicate species-specific differences in the phosphorylation of mouse and rat
p53
in SV40-transformed cells, reflected by (i) different turnover rates at specific sites in mouse and rat
p53
and (ii) phosphorylation of nonhomologous
serine
and threonine residues in rat
p53
, as revealed by indirect assignment of phosphorylation sites to the phosphopeptides of rat
p53
. Analyses of
p53
from the SV40 tsA58 mutant-transformed F111 cell lines FR(tsA58)A (N type) and FR(tsA58)57 (A type) yielded no conclusive evidence for a direct correlation between phosphorylation of
p53
, the metabolic stabilization of
p53
, and expression of the transformed phenotype.
...
PMID:Species-specific phosphorylation of mouse and rat p53 in simian virus 40-transformed cells. 131 85
Lymphocyte activation requires signal transduction mediated by reversible phosphorylation. Changing profiles of phosphorylated intermediates relate to the progressive series of transduction pathways in cells moving from G0 to G1, and thereafter through the cell cycle. We have previously shown that transient inhibition of the
serine
/threonine protein phosphatases PP1 and PP2A by okadaic acid enhances early mitogenic stimulation. Thus target proteins of PP1/PP2A may be involved in regulation of early mitogenic signalling, with the phosphorylated form(s) being associated with signal enhancement. Later, pathways require dephosphorylation of these proteins, since continuous treatment with okadaic acid blocks lymphocyte progression through the cell cycle. Delayed addition of okadaic acid showed that this blockade occurs between 8 and 24 hr. Here we have furthered these observations to the level of gene induction by measuring messenger RNA (mRNA) levels for the following proteins: interleukin-2 (IL-2) and IL-2R alpha;
p53
, a tumour suppressor protein; the transcription factor krox-24; and two mediators of protein folding, namely cyclophilin and the heat-shock protein hsc70. An external standard was used to quantitate the mRNA levels per cell. We found that 24 hr exposure to okadaic acid has a general suppressive effect on concanavalin A (Con A)-stimulated gene induction. However, at 4 hr okadaic acid enhanced IL-2 mRNA levels induced by Con A. Moreover, in unstimulated lymphocytes, okadaic acid caused the induction of krox-24, indicating a role for PP1 and PP2A in the regulation of this gene in resting cells.
...
PMID:Inhibition of the serine/threonine protein phosphatases PP1 and PP2A in lymphocytes: effect on mRNA levels for interleukin-2, IL-2R alpha, krox-24, p53, hsc70 and cyclophilin. 132 40
We have cloned and sequenced the
p53
-encoding cDNA of rainbow trout (Salmo gairdneri). The encoded product contains the characteristics found in all
p53
proteins: (i) the five highly conserved domains, (ii) an acidic N terminus, (iii) a hydrophilic C terminus, and (iv) a penultimate
serine
residue. Furthermore, we demonstrate that the rainbow trout
p53
is able to specifically interact with the SV40 large T antigen.
...
PMID:Rainbow trout p53: cDNA cloning and biochemical characterization. 133 62
Human DNA-PK is a nuclear, serine/threonine protein kinase that, when activated by DNA, phosphorylates several DNA-binding substrates, including the
tumor suppressor protein p53
. To identify which
p53
residues are phosphorylated, we examined DNA-PK's ability to phosphorylate synthetic peptides corresponding to human
p53
sequences. Serines 15 and 37 in the amino-terminal transactivation domain of human
p53
, and serines 7 and 18 of mouse
p53
, were phosphorylated by DNA-PK in the context of synthetic peptides. Other serines in these
p53
peptides, and serines in other
p53
peptides, including peptides containing the
serine
315 p34cdc2 site and the
serine
392 casein kinase II site, were not recognized by DNA-PK or were phosphorylated less efficiently. Phosphorylation of the conserved
serine
15 in human
p53
peptides depended on the presence of an adjacent glutamine, and phosphorylation was inhibited by the presence of a nearby lysine. Phosphorylation of recombinant wild-type mouse
p53
was inhibited at high DNA concentrations, suggesting that DNA-PK may phosphorylate
p53
only when both are bound to DNA at nearby sites. Our study suggests that DNA-PK may have a role in regulating cell growth and indicates how phosphorylation of
serine
15 in DNA-bound
p53
could alter
p53
function.
...
PMID:Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. 140 79
The monoclonal antibody (mAb) 1801 has been reported to identify an N-terminal determinant within the tumor-suppressor
protein p53
located between amino acids 32 and 79. This region contains two potential sites for
serine
phosphorylation at amino acids 33 and 46. Using a novel technique which dephosphorylates proteins in situ in fixed permeabilized cells, we have unmasked determinants in
p53
recognized by mAb 1801, allowing additional sites of
p53 protein
to be detected in immunohistochemically reacted cells. This result indicates that phosphorylation at one or both sites within the determinant recognized by mAb 1801 previously blocked antibody-ligand interaction. It further suggests that in situ dephosphorylation may be of more general use in identifying antibodies which can only bind to epitopes in a particular phosphorylation state.
...
PMID:In situ dephosphorylation of p53 protein by calf intestinal alkaline phosphatase treatment. 143 59
Human cyclin B1-bound cdc2 kinase phosphorylated the threonine residue in the sequence -Thr-Pro-Lys-Lys-Ala- but hardly phosphorylated it in the sequence -Thr-Pro-Lys-Ala-Lys. The sequence -Thr-Pro-Ala-Pro-Lys-, as found in
p53 protein
, was also phosphorylated by this enzyme, but less efficiently than in the sequence described above. When the threonine residue in -Thr-Pro-Lys-Lys-Ala- was changed to a
serine
or a tyrosine residue, the enzyme phosphorylated the
serine
, but not the tyrosine residue. Changing the lysine next to the proline to alanine reduced its efficiency as a substrate. The peptide, Ala-Ala-Ala-Ala-Lys-Thr-Pro-Ala-Lys-Ala-Ala, containing the -Thr-Pro-Ala-Lys- sequence, but not the other lysine residues, was not used as a substrate by the kinase.
...
PMID:Preference of human cdc2 kinase for peptide substrate. 145 May 22
The
p53
tumour suppressor protein is phosphorylated by several protein kinases, including casein kinase II. In order to understand the functional significance of phosphorylation by casein kinase II, we have introduced mutations at
serine
386 in mouse
p53
, the residue phosphorylated by this kinase, and investigated their effects on the ability of
p53
to arrest cell growth. Replacement of
serine
386 by alanine led to loss of growth suppressor activity, while aspartic acid at this position partially retained suppressor function. These data suggest that the anti-proliferative activity of
p53
is activated by phosphorylation at
serine
386, and establish a direct link between the covalent modification of a growth suppressor protein and regulation of its activity in mammalian cells.
...
PMID:Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53. 145 21
The
p53
gene was examined in primary or metastatic tumors from six patients with rhabdomyosarcoma (RMS) and in five RMS cell lines by screening methods including single-strand conformation polymorphism analysis, the RNase protection assay, sequencing of complementary DNA subclones, and Southern blotting. Six original tumors were of embryonal histology, four alveolar, and one mixed.
p53
mutations were identified in four of the six tumors or cell lines derived from tumors with embryonal histology and in one of the four with alveolar histology. Consistent with
p53
allele loss, each mutation was found in the homo- or hemizygous state. One tumor showed a G to C transversion at
p53
codon 213 (arginine to proline), and another showed deletion of the entire gene. The
p53
mutations in cell lines included a codon 248 C to T transition (arginine to tryptophan) in RD and a codon 280 A to T transversion (arginine to
serine
) in RH30. The cell line CTR contained a 4-base pair deletion at codons 219/220 in exon 6 with resultant frame shift and premature termination in exon 7. These data support the role of diverse types of
p53
mutations in the pathogenesis and/or progression of a significant proportion of cases of childhood RMS.
...
PMID:Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. 155 27
Phosphorylation is an attractive mechanism for regulating the functions of
p53
. The p34cdc2 kinase, which is involved in regulation of the cell cycle, phosphorylates
serine
-315 of human
p53
in vitro. Casein kinase II phosphorylates
serine
-389 of mouse
p53
in vitro. The amino-terminal region of mouse
p53
contains a cluster of potential
serine
phosphorylation sites. Those sites have been proposed to be sites for phosphorylation by a double-stranded DNA-dependent kinase (DNA-PK) from HeLa cells and can be dephosphorylated by protein phosphatase 2A. To identify in vivo phosphorylation sites in the amino-terminal region of mouse
p53
, we mutated potential phosphorylation sites and analyzed the mutant proteins by tryptic phosphopeptide mapping. We identified
serine
-7, -9, -18, and -37 as in vivo phosphorylation sites. We further showed that mouse
p53
expressed in bacteria is phosphorylated by DNA-PK on amino-terminal
serine
residues in vitro.
...
PMID:Phosphorylation sites in the amino-terminal region of mouse p53. 158 57
1
2
3
4
5
6
7
8
9
10
Next >>